Anonymous
Guest
Anonymous
Guest
Anyone tired of of dead weight like losing 20 million a year. Lets boost our oncology numbers by laying off the neuro franchise as been discussed before. They were so grim and blah at biltmore. If they can't get 10% market share on the same molecule, why keep them. How many years of losing money we endure? Time to cut the cancer out of Ipsen out.